000151171 001__ 151171
000151171 005__ 20251017144609.0
000151171 0247_ $$2doi$$a10.3390/ph14080759
000151171 0248_ $$2sideral$$a125277
000151171 037__ $$aART-2021-125277
000151171 041__ $$aeng
000151171 100__ $$aLopez-Tejedor, David
000151171 245__ $$aIn Vitro Antiviral Activity of Tyrosinase from Mushroom Agaricus bisporus against Hepatitis C Virus
000151171 260__ $$c2021
000151171 5060_ $$aAccess copy available to the general public$$fUnrestricted
000151171 5203_ $$aTyrosinases from a commercial Agaricus bisporus protein extract and directly isolated from white mushrooms were purified in order to obtaining the well-known tyrosinase from A. bisporus (TyrAB) of 45 kDa and a newly discovered 50 kDa tyrosinase isoform (Tyr50 kDa), and tested showing high antiviral activity against the hepatitis C virus for the first time. Cell toxicity and antiviral activity of tyrosinases were determined in cultured Huh 5-2 liver tumor cells transfected with a replicon system (a plasmid that includes all non-structural hepatitis C virus proteins and replicates autonomously). TyrAB was able to inhibit the replication of the hepatitis C virus without inducing toxicity in liver cells. In addition, the post-translational isoform Tyr50 kDa showed higher antiviral capacity than the former (up to 10 times greater), also exhibiting 10 times higher activity than the commercial drug Ribavirin\u00ae. This antiviral activity was directly proportional to the enzymatic activity of tyrosinases, as no antiviral capacity was observed in the inactive form of the enzymes. The tyrosinases approach could represent a new antiviral inhibition mechanism, through a plausible catalytic mechanism of selective hydroxylation of the key role of tyrosine residues in viral proteases.
000151171 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B25-17R$$9info:eu-repo/grantAgreement/ES/DGA/E45-17R$$9info:eu-repo/grantAgreement/ES/ISCIII/CPII13-00017$$9info:eu-repo/grantAgreement/ES/ISCIII-ERDF-ESF/PI15-00663-Investing in your future$$9info:eu-repo/grantAgreement/ES/ISCIII-ERDF-ESF/PI18-00349-Investing in your future$$9info:eu-repo/grantAgreement/ES/MCIU-AEI-FEDER/BFU2013-47064-P$$9info:eu-repo/grantAgreement/ES/MCIU-AEI-FEDER/BFU2016-78232-P
000151171 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000151171 590__ $$a5.215$$b2021
000151171 591__ $$aPHARMACOLOGY & PHARMACY$$b69 / 279 = 0.247$$c2021$$dQ1$$eT1
000151171 591__ $$aCHEMISTRY, MEDICINAL$$b16 / 63 = 0.254$$c2021$$dQ2$$eT1
000151171 592__ $$a0.851$$b2021
000151171 593__ $$aPharmaceutical Science$$c2021$$dQ1
000151171 593__ $$aDrug Discovery$$c2021$$dQ1
000151171 594__ $$a4.0$$b2021
000151171 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000151171 700__ $$aClaveria-Gimeno, Rafael
000151171 700__ $$0(orcid)0000-0001-5702-4538$$aVelazquez-Campoy, Adrian$$uUniversidad de Zaragoza
000151171 700__ $$0(orcid)0000-0001-5664-1729$$aAbian, Olga$$uUniversidad de Zaragoza
000151171 700__ $$aPalomo, Jose M.
000151171 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000151171 773__ $$g14, 8 (2021), 759 [12 pp.]$$pPharmaceuticals$$tPharmaceuticals$$x1424-8247
000151171 8564_ $$s3471209$$uhttps://zaguan.unizar.es/record/151171/files/texto_completo.pdf$$yVersión publicada
000151171 8564_ $$s2441667$$uhttps://zaguan.unizar.es/record/151171/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000151171 909CO $$ooai:zaguan.unizar.es:151171$$particulos$$pdriver
000151171 951__ $$a2025-10-17-14:16:38
000151171 980__ $$aARTICLE